A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Recruiting · Phase 1 · NCT07015697
Conditions: Recurrent or Metastatic Solid Tumors
At a glance
- Research payments reported, 2025
- $182,345
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 76
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- Trastuzumab Deruxtecan (drug)
- Dates
- Started 2025-07-17; completion 2028-12-31
- Results posted
- Not yet
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $182,345 in research payments for this study in 2025 (17 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manali A. Bhave, MD Medical Oncology · Chicago, IL
- Antoinette R. Tan, MD Medical Oncology · Charlotte, NC
- John J. Nemunaitis, MD Medical Oncology · Toledo, OH
- Erika P. Hamilton, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Taylor Family Research Foundation Dba Taylor Cancer Research Center $81,225
- Sarah Cannon Research Institute $39,250
- Wake Forest University Health Sciences $34,880
- Emory University Hospital, GA $26,990
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.